Advanced searches left 3/3

Inflammatory Bowel Disease - Europe PMC

Summarized by Plex Scholar
Last Updated: 08 August 2022

* If you want to update the article please login/register

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease.

Patients with inflammatory bowel disease are often diagnosed with ankylosing spondylitis. Methods Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 percent of those with AS were also diagnosed with AS. Conclusions The number of patients treated with biologics or small molecule therapies in the IBD-AS group was significantly higher in the IBD-AS group than in the IBD-only group. Patients with both ulcerative colitis and AS had a higher risk of biologics or small molecule therapies than those with only ulcerative colitis.

Source link: https://europepmc.org/article/MED/35929093


Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?

No published studies have been published on AAC in inflammatory bowel disease. AAC was found in 36. 7 percent of IBD patients, relative to 30. 6% of controls. Moderate-severe grade of AAC was found in 35. 7% of IBD patients in comparison to 30. 6% in controls. Patients of cardiovascular and ulcerative colitis had significantly higher incidences of more severe atherosclerotic lesions. Multiple disease and lifetime steroids were identified as independent risk factors for AAC, according to a multivariate review after excluding CVD risk confounders for non-CVD patients. Use of the anti-tumor necrosis factor (u03b1) in non-CVD IBD patients was not correlated with AAC deposition. Conclusions More than a third of IBD patients have moderate to severe AAC.

Source link: https://europepmc.org/article/MED/35929091


Clinical spectrum of elderly-onset inflammatory bowel disease in India.

Background/Objectives In elderly patients, Inflammatory bowel disease is increasingly evident. From India, there is no data on the clinical nuances of elderly-onset IBD patients. Methods A cross-sectional retrospective review of a prospectively stored registry of patients with IBD was conducted at two centers in India. IBD in older adults was compared with adult-onset IBD, including demographic information, clinical presentation, disease characterization, and treatment. Diarrhea, blood in stools, nocturnal prevalence, and pain abdomen were among the most typical UC presentations, although pain abdomen, weight loss, and diarrhea were among the most common symptoms in CD. The overwhelming majority of patients had moderately severe disease at both onset UC and CD. In an older onset IBD, the prevalence of colorectal cancer was at an all time. Both the elderly onset UC and CD were milder, with no significant differences in disease morphology when compared to adult-onset IBD.

Source link: https://europepmc.org/article/MED/35929090


Impact of Disease Activity and Inflammatory Bowel Disease Subtype on Quality of Life in Preconception and Pregnant Patients.

Aims is a company that uses questionnaires to investigate HRQoL in pre-conception and pregnant patients with Crohn's disease and ulcerative colitis. Preconception and pregnant patients with IBD were followed longitudinally from preconception to twelve months postpartum at a tertiary referral center. Participants completed the Short IBD Questionnaire and were screened for cardiovascular disease prevalence and objective disease activity. During preconception, patients with UC had higher SIBDQ bowel and social sub-scores than those with CD, but this changed during postpartum. Patients with CD, but not UC, achieved a substantial rise in SIBDQ after becoming pregnant, which persisted into 12 months postpartum. Patients with FCP u2265 250 mg/kg at T2, T3, and 6 months postpartum had significantly lower sub-scores in SIBDQ bowel sub-scores, according to some. Patients with UC have improved preconception HRQoL, but they have lower postpartum HRQoL than those with CD.

Source link: https://europepmc.org/article/MED/35930124


Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients.

Ibid patients with iron deficiency are multifactorial, with intestinal bleeding, malabsorption, and inadequate oral intake. Patients with active inflammation have regular screening and diagnosis, and many patients have mixed iron deficiency anemia and chronic disease anemia. While oral iron is safe, affordable, and simple to administer, patients often suffer from intolerable gastro-side effects, and in IBD patients, oral iron can elevate inflammation and contribute to flares. Therefore, although it is heavily underused, intravenous iron is considered first-line therapy for patients with active disease, severe anemia, oral iron intolerance, and erythropoietin requirements. Many IV iron formulations are available, and iron sucrose and ferric carboxymaltose are the most commonly used and well studied in patients with IBD. Patients with IBD are likely to have screening, diagnosis, and treatment of iron deficiency anemia.

Source link: https://europepmc.org/article/MED/35930123


Inflammatory bowel disease in families with four or more affected first-degree relatives.

However, studies on variation in phenotypic characteristics in patients with a family history of IBD are difficult and conflictual. The aim of the study was to determine the phenotypic characteristics of IBD patients with four or more affected first-degree relatives with sporadic cases of IBD. Methods Patients with familial and sporadic IBD were identified from the institutional IBD database. Patients from at least four first-degree affected families were selected for analysis and compared to non-matched sporadic cases with IBD randomly selected randomly. Thirty-five patients with familial IBD were compared to 88 sporadic IBD patients. Patients with familial versus sporadic IBD were more likely to require steroid therapy, biological diagnosis, or surgery. Conclusions IBD with a long positive family history is linked to younger age at onset and a more complicated IBD phenotype than sporadic IBD.

Source link: https://europepmc.org/article/MED/35929993


Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.

Background We compared the risks of nonmelanoma skin cancers and melanoma before and after a diagnosis of inflammatory bowel disease, we investigated the effect of thiopurines and anti-tumor necrosis factor u03b1 on skin cancer risk in IBD. Persons with ulcerative colitis were more likely to have basal cell carcinoma predating their UC diagnosis. Symptoms of BCC and SCC were significantly elevated across all IBD groups except for SCC in UC. People with IBD with censorship at both thiopurines and anti-TNF tested revealed a higher risk of BCC and no impact on SCC, according to pre-IBD diagnosis results. Conclusions BCC preceding a diagnosis of UC is higher than in non-UC settings, although it is still at a higher risk of all NMSCs post-IBD diagnosis. People with IBD who have had a diagnosis of skin cancer are at a greater risk of skin cancers in people with IBD. Thiopurine and anti-TNF therapy have both raised the risk of skin cancer in people with IBD.

Source link: https://europepmc.org/article/MED/35929649


Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019.

Background information about mucosal healing with colonoscopy is recommended for inflammatory bowel disease control; however, little is known about real-world use of targeted-to-target monitoring following IBD treatment initiation. In the three to fifteen months after beginning treatment, we wanted to determine the proportion of commercially insured IBD patients who had colonoscopy in the United States. Methods We found IBD patients aged 18 to 64 years of age in the IBM MarketScan Commercial Claims and Encounters database as those with u22653 IBD diagnoses prior to initiating biologic, small molecule, or immunomodulatory therapy before beginning of biologic, small molecule or immunomodulatory therapy. We used Kaplan-Meier methods to estimate the number of newly treated IBD patients who had colonoscopy in the 3 to 12 months, 3 to 12 months, and 3 to 15 months after treatment began, stratified results by year, patient age and sex, and region.

Source link: https://europepmc.org/article/MED/35929644


Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease.

Endoscopy remains the reference standard for the diagnosis and evaluation of patients with inflammatory bowel disease, but it does have several significant drawbacks. Endoscopic findings of mucosal inflammation in the colon and terminal ileum were strongly related to a variety of cross-sectional imaging studies. Unlike endoscopy, cross-sectional procedures allow complete visualization of the small-bowel and assessing for extraintestinal disease, which occurs in almost half of patients with IBD. This review discusses cross-sectional imaging in IBD in current clinical practice as well as research lines that will help determine the future use of these technologies.

Source link: https://europepmc.org/article/MED/35927032


Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of Inflammatory Bowel Disease using the AGREE II instrument: A Systematic Review.

Historically, the incidence and diagnosis of inflammatory bowel disease have greatly increased in recent years. Using the Appraisal of Guidelines for Research and Evaluation instrument, we sought to consistently assess the quality of CPGs for the diagnosis and treatment of IBD. We provided IBD diagnostic and treatment guidelines and analyzed them with the AGREE II device to determine their methodological reliability. In two years, from 2012 to 2017, and from 2018 to 2022, We assessed the degree of agreement using the intraclass correlation coefficient, and change in quality over time was measured. "Scope and purpose," 84. 5 percent, "Stakeholder involvement" 60. 9 percent, "Clarity of presentation" 69. 95 percent, "Applicability" 26. 6 percent, and "Editorial independence" 62. 02% were among the AGREE II domains' mean scores. It's also improved that efforts to produce high quality CPGs for IBD.

Source link: https://europepmc.org/article/PPR/PPR528104

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions